咖啡酸治疗伊马替尼致慢性粒细胞白血病患者血小板、白细胞减少的临床观察

摘要

Objective To investigate the curative effect and adverse reaction of caffeic acid (CFA) for leukopenia and thrombocytopenia caused by imatinib in chronic myeloid leukemia (CML) patients.Methods The effect and adverse reactions of CFA for leukopenia or thrombocytopenia induced by imatinib in 42 CML patients were observed.The CFA was admitted by 0.2 g/time,3 times/d,oral.Results 21 cases of 42 CML patients with thrombocytopenia achieved remarkable curative effect after CFA treatment,13 achieved good effect and 8 had no effect.The total effective rate was 81.0 ％ (34/42).While 15 of 28 leukopenia CML patients achieved remarkable curative effect,8 achieved good effect and 5 had no effect.The total effective rate was 82.1％ (23/28).After CFA therapy for 2 weeks,both platelet and white blood cells count were elevated compared with before treatment,the differences were statistically significant (t =2.015,P =0.023,t =1.913,P =0.035).The average onset time of CFA for leukopenia and thrombocytopenia was 2 weeks and no treatment-related adverse reaction was found.Conclusion CFA is an effective and safe auxiliary drug for treatment of imatinib-induce leukopenia and thrombocytopenia in patients with CML.%目的 观察咖啡酸(CFA)对伊马替尼致慢性粒细胞白血病(CML)患者血小板、白细胞减少的临床疗效和患者不良反应.方法 对42例应用伊马替尼治疗后出现血小板、白细胞减少的CML患者,血小板和(或)白细胞减少时即开始应用CFA,0.2 g/次,3次/d,口服,观察治疗过程中血小板、白细胞变化情况和患者不良反应.结果 治疗血小板减少42例,其中显效21例,良效13例,无效8例,总有效率81.0 ％(34/42)；治疗白细胞减少28例,其中显效15例,良效8例,无效5例,总有效率82.1％(23/28);治疗第2周时血小板、白细胞计数与治疗前相比差异有统计学意义(t=2.015,P=0.023;t=1.913,P=0.035)；CFA治疗有效患者的平均起效时间为2周.未发现治疗相关不良反应.结论 CFA治疗伊马替尼所致的CML患者血小板、白细胞减少疗效确切,无明显不良反应,是CML治疗过程中安全有效的辅助治疗药物.